Pharmaceutical Technology
APRIL 24, 2023
With new drugs on the market, companies are now looking for ways to manufacture recently approved biologics, and countries are racing to claim their corner – or maintain their decades-old market share. ” The number of contracting facilities in India is smaller than in the US, but the industry there is growing rapidly.
Fierce Pharma
AUGUST 3, 2023
The division took a major hit from production timing and COVID-related sales downturns. The division took a major hit from production timing and COVID-related sales downturns.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 26, 2023
PWC predicts deal volumes to resemble prior years with the effect of the US Inflation Reduction Act on pricing better understood and less uncertainty surrounding business conditions, according to an article entitled Pharmaceutical & Life Sciences: US Deals 2023 Outlook published on the company’s website.
XTalks
JANUARY 29, 2021
Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. Merck’s Keytruda ($7.2B) and BMS’s Opdivo ($1.8B) hold the number 2 and number 11 spots, respectively, in annual sales of the top oncology products. Keytruda (Pembrolizumab) and Opdivo (Nivolumab).
The Pharma Data
JANUARY 5, 2021
6, 2021 /PRNewswire/ — The life science company Sartorius today announced it has entered into an agreement through its subgroup Sartorius Stedim Biotech to acquire the chromatography process equipment division of Novasep. . In fiscal 2019, the company earned sales revenue of some 1.83 About Sartorius. billion euros.
The Pharma Data
NOVEMBER 5, 2020
is a rapidly growing generic pharmaceutical company in the United States devoted to discovery, manufacture, sale, and distribution of prescription generic pharmaceutical products. About Jubilant Cadista Pharmaceuticals Inc. Jubilant Cadista Pharmaceuticals Inc. View original content to download multimedia: [link].
The Pharma Data
OCTOBER 27, 2020
While we are deliberately sector generalists, some of our primary interest areas include Medical Products, Industrial Technology, Life Sciences, Aerospace & Defense, and Specialty Materials. We approach investments from multiple perspectives but share a single vision – to identify and unlock the breakout potential in our companies.
Expert insights. Personalized for you.
130 
Let's personalize your content